China SXT Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $28.2M | $18.1M | $12.1M | $17.4M | $15.6M | $13.4M | $7.3M | $9.3M |
| Accounts Receivable | $931.6K | $1.3M | $1.3M | $1.3M | $3.3M | $4.5M | $3.8M | $4.2M |
| Inventory | $777.1K | $828.1K | $794.9K | $531.3K | $1.0M | $859.7K | $892.8K | $1.0M |
| Total Current Assets | $34.5M | $21.3M | $14.2M | $19.5M | $22.5M | $23.2M | $19.6M | $15.6M |
| Property, Plant & Equipment | $117.1K | $178.6K | $328.8K | $962.2K | $1.2M | $1.4M | $1.6M | $1.2M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $6.3K | $11.8K | $19.1K | $27.9K | $38.8K | $45.8K | $50.1K | $61.1K |
| Total Assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M |
| Liabilities | ||||||||
| Accounts Payable | $497.6K | $1.2M | $1.3M | $1.4M | $1.5M | $1.5M | $1.9M | $1.7M |
| Total Current Liabilities | $4.3M | $6.0M | $8.9M | $14.5M | $17.1M | $18.6M | $12.3M | $6.3M |
| Long-Term Debt | $644.4K | $96.3K | $117.1K | $117.9K | — | $6.3K | $36.5K | $41.7K |
| Total Liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M | $12.3M | $6.4M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-34.2M | $-28.0M | $-24.7M | $-21.6M | $-15.7M | $-10.0M | $-7.2M | $3.1M |
| Total Stockholders' Equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M | $9.4M | $11.1M |